新医改体制下中成药制造成本分析优化

Analysis and optimization on production cost of Chinese medicine under the new medical reform

中药作为我国医药行业中有比较优势的行业,在新医改前一直处于高毛利时代。在以产品为中心的传统营销模式下,企业的产品质量升级、成本增加,可以通过高定价来转移竞争压力,从而依然获得较高的企业利润。在新医改模式下,招标价越走越低;而原辅材料价格持续攀升,人力成本快速上涨,更多产品质量标准进一步提高,所有这些成本上涨因素不再能够通过提高招标价而转移。企业的利润必将受到较大的影响,企业要维系股东、客户、员工三方的利益平衡,必须从系统上彻底优化成本竞争力才能生存。面对市场变化,企业应该调整经营思路,把经营重心由以外部市场为主,向内外兼修偏移,营建系统思维的经营模式,强调与医改政策趋势相一致的内部管控模式,促成企业的战略创新和理念创新,以此来优化制药企业全面的市场竞争能力。

As one comparative industry, Chinese medicine has been always in high gross profit. In the traditional marketing model of which the product was the center,the quality of the product was improved and the cost was increased, high profit can still be obtained through transferring the competition pressure to high price. However, in the new medical reform mode the cost increase can＇ t be transferred to price increase because the price is getting lower but the raw material and the manpower cost continue to rise and quality standard of the products is further improved, thus the profits of enterprises will be affected by all these factors. The enterprise must optimize cost competitiveness from system thoroughly in order to survive and to keep benefit balance between shareholders, customers and employees. Enterprises should adjust the operation mode through transferring the focus from the market to the internal management as well as the market to construct system thinking operation mode,and also should strengthen the management model that consist with the new medical reform to promote enterprise strategic innovation and concept innovation,in order to optimize market competition ability.